Advertisement
Advertisement
U.S. Markets open in 2 hrs 24 mins
Advertisement
Advertisement
Advertisement
Advertisement

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.1600+0.0800 (+3.85%)
At close: 01:00PM EST
2.1600 0.00 (0.00%)
Pre-Market: 06:20AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0800
Open2.1200
Bid0.0000 x 800
Ask0.0000 x 1400
Day's Range2.1100 - 2.6799
52 Week Range1.8600 - 8.4500
Volume959,953
Avg. Volume433,939
Market Cap135.091M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-2.4150
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • Business Wire

    Omeros Corporation Reports Third Quarter 2022 Financial Results

    SEATTLE, November 09, 2022--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022, which include:

  • Business Wire

    Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

    SEATTLE, November 08, 2022--Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company’s formal dispute resolution request appealing the issuance by FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) and the Division of Nonmalignant Hematology (the review division) of a complete response letter (CRL) concerning the biologics license application (BLA) for narsop

  • Business Wire

    Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

    SEATTLE, November 04, 2022--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.

Advertisement
Advertisement